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Background: mRNA electroporation of dendritic cells (DCs) facilitates processing and presentation of multiple
peptides derived from whole antigen, tailored to different HLA molecules. Clinical responses to electroporated
moDC vaccines, however, have been suboptimal. Human Langerhans-type DCs (LCs) are the most potent
conventional DC subtype for inducing CD8+ cytotoxic T lymphocytes (CTLs) in vitro. We recently demonstrated that
Wilms’ tumor 1 (WT1) mRNA-electroporated LCs are superior to moDCs as stimulators of tumor antigen-specific
CD8+ CTLs, even though they are comparable stimulators of allogeneic T cell proliferative responses. A detailed
comparative evaluation of the effects of mRNA electroporation on LCs versus moDCs, however, is needed.
Methods: Immature and partially-matured human moDCs and LCs electroporated with mRNA were compared for
transfection efficiency, phenotypic changes, viability, retention of transgene expression after cryopreservation, and
immunogenicity. Student t test was used for each pairwise comparison. One-way analysis of variance was used for
multiple group comparisons.
Results: Transfection efficiency after electroporation with enhanced green fluorescent protein (eGFP) mRNA was
higher for immature than for partially-matured moDCs. In contrast, transfection efficiency was higher for partially-
matured than for immature LCs, with the additional benefit that electroporation itself increased maturation and
activation of CD83+HLA-DRbright LCs but not moDCs. Electroporation did not impair final maturation and activation
of either DC subtype, after which both mRNA-electroporated LCs and moDCs were functionally similar in
stimulating allogeneic T cell proliferation, a standard assay of DC immunogenicity.
Conclusions: These findings support mRNA electroporation of DCs, and in particular LCs, as an effective non-viral
method to stimulate specific, potent CD8+ CTL responses. The differences between LCs and moDCs regarding this
form of antigen-loading have important implications for DC-based immunotherapies.
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Effective therapeutic cancer vaccination requires the op-
timization of tumor antigen presentation by antigen-
presenting cells (APCs) to induce strong antigen-specific
T cell responses, especially CD8+ cytolytic T lympho-
cytes (CTLs) with a sufficiently broad repertoire and im-
munologic memory [1]. Human conventional dendritic
cells (DCs) are the most potent APCs and are critical to
the onset of immunity. DCs prime T cell responses by
coupling antigen to all the requisite co-stimulatory, cyto-
kine, and chemokine signals required for the activation
of naive and resting T cells [2]. Numerous studies have
demonstrated the feasibility of DC-based immunization
to induce host responses against tumors [3].
Electroporation of DCs with mRNA encoding specific
tumor-associated antigens is an effective non-viral me-
thod to stimulate T cell responses in vitro and in vivo
[4-11]. This method of antigen loading, which facilitates
processing and presentation of multiple class I and II
MHC-restricted epitopes from the translated protein
[12], is more efficient than peptide pulsing and less
problematic than retroviral transgenes, which carry the
risk of genome integration [13]. mRNA electroporation
also allows individuals of any HLA type to process and
present peptides tailored to their own MHC molecules.
Monocyte-derived DCs (moDCs) are the most com-
monly used DC subtype in cancer vaccines, and the
induction of tumor-specific CTLs in vitro by mRNA-
transfected moDCs has been reported in several studies
[4-10]. Clinical responses to moDC-based vaccines, how-
ever, have not always achieved optimal stimulation of
antigen-specific CTLs; and data on clinical responses to
vaccination with mRNA-electroporated moDCs are li-
mited [7,11].
Human Langerhans-type DCs (LCs) derived from
CD34+ hematopoietic progenitor cells are the most po-
tent conventional DC subtype for stimulating CD8+
CTLs in vitro [14-17]. We recently showed that WT1
mRNA-electroporated LCs are superior to moDCs as
stimulators of antigen-specific CTLs in vitro, using an
IL15R-α/IL15/pSTAT5-dependent mechanism [16]. LCs
synthesize abundant IL15 mRNA and protein, whereas
moDCs are dependent on exogenous IL15 for stimulat-
ing comparably potent WT1-specific CTLs [16]. The ef-
fects of mRNA electroporation on moDCs have been
described [18]. A detailed comparative evaluation of the
effects of mRNA electroporation on LCs versus moDCs
is still needed, however.
In this study, we compared moDCs and LCs after
mRNA electroporation for transfection efficiency, phe-
notypic changes, viability, retention of transgene ex-
pression after cryopreservation, and allo-stimulatory
capacity. Our findings clearly demonstrate that the ma-
turation state of moDCs and LCs differentially affectstheir susceptibility to electroporation, and electropo-
ration itself has a useful maturational effect on LCs but
not moDCs. These findings underscore the importance
of tailoring electroporation conditions to specific DC
subtypes when designing DC-based immunotherapies.
Methods
Blood samples
Peripheral blood mononuclear cells (PBMC) or granulo-
cyte colony stimulating factor (G-CSF)–elicited CD34+
hematopoietic progenitor cells (HPC) were obtained
from healthy volunteers or allogeneic hematopoietic
stem cell transplant donors. Buffy coats purchased from
the Greater New York Blood Center, American Red
Cross, were also used as a source of cells from healthy
donors. Biospecimen sample collection and use adhered
to protocols approved by the Institutional Review and
Privacy Board of Memorial Hospital, Memorial Sloan-
Kettering Cancer Center (MSKCC).
Media, serum, and non-cytokine reagents
For moDC cultures, complete RPMI 1640 was supplemen-
ted with 10 mM HEPES (N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid), 1% penicillin/streptomycin
(Media Laboratory, MSKCC), 50 μM 2-mercaptoethanol
(GibcoBRL Life Technologies), 2 mM L-glutamine
(GibcoBRL), and heat-inactivated, autologous single-
donor or pooled human serum (1% or 10% vol/vol). For
LC cultures, X-VIVO 15 (BioWhittaker) was only sup-
plemented with cytokines (see below). All media and re-
agents were endotoxin-free.
Generation of moDCs and LCs with recombinant human
cytokines
MoDCs were generated from PBMCs, and LCs were gener-
ated from G-CSF–elicited CD34+ HPCs. Media, media sup-
plements, and cytokines were exactly as published [14]. In
brief, for immature moDC generation, tissue culture plastic
adherent CD14+ monocytes were cultured in complete
RPMI-1% normal human serum (NHS) with GM-CSF and
IL-4 for 5 to 6 days. For immature LC generation, CD34+
HPCs were cultured in serum-free X-VIVO 15,
supplemented with GM-CSF, TGF-β, and TNF-α, to which
c-kit-ligand and FLT-3-ligand were added for only the first
5 to 6 days of a 10- to 12-day culture. Terminal maturation
of moDCs and LCs was induced with a combination of
TNF-α, IL-1β, IL-6, and prostaglandin E2.
T lymphocytes
T cells were obtained from tissue culture plastic-
nonadherent PBMCs, further purified by nonadherence
and elution from nylon wool columns (Polysciences).
This achieved >95% purity without bystander activation
of T cells.
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An eGFP-containing plasmid, pGEM4Z/eGFP/A64, was
obtained from Dr. E. Gilboa, University of Miami. For
WT1, an EcoRI insert encoding WT1 cDNA, derived
from the pUC119 plasmid (Riken Bioresource), was
cloned into a pGEM-4Z vector (Promega). Plasmids were
propagated in Max Efficiency DH5-α competent cells
(Invitrogen) and purified using a Plasmid Maxi Kit
(QIAGEN).
Production of in vitro–transcribed mRNA
For eGFP mRNA transcription, the pGEM4Z/eGFP/A64
plasmid was linearized with SpeI (New England Biolabs)
before mRNA transcription in vitro, which was perfor-
med with T7 RNA polymerase (mMessage mMachine
T7 kit; Ambion). For WT1 mRNA transcription, the
pGEM-4Z/WT1 plasmid was linearized with HindIII
(New England Biolabs) before mRNA transcription
in vitro, which was performed with SP6 RNA polymer-
ase (mMessage mMachine SP6 kit; Ambion). For both
eGFP and WT1 mRNA, agarose gel electrophoresis con-
firmed production of full-length capped mRNA, and
spectrophotometry measured mRNA concentration.
Electroporation of cells
Immature moDCs were electroporated on day 5–6 and im-
mature LCs on day 10–11. Partially-matured moDCs were
electroporated on day 7–8 and partially-matured LCs on
day 12–13, reflecting the different times required to gener-
ate these two DC subtypes in vitro [14,15]. After harvesting,
cells were washed twice and resuspended in OptiMEM
(Gibco, Invitrogen) at 15×106 cells/ml. 200 μL of cell sus-
pension were then mixed with 20–40 μg mRNA and
electroporated in a 2 mm gap cuvette at 650–900 V for
1–3 pulses at 0.5 msec/pulse, using a BTX ECM 830
square-wave electroporator (BTX Harvard). After elec-
troporation, cells were immediately transferred to cul-
ture to minimize cell death. While in culture, immature
cells were partially or terminally matured by exposure to
inflammatory cytokines for 24 or 48 hours, respectively.
Phenotypic and eGFP expression analyses by flow
cytometry
Fluorescein (FITC)-, phycoerythrin (PE)-, PE-cyanine
-7–, and allophycocyanin (APC)–conjugated mouse
anti–human monoclonal antibodies included anti-CD80,
anti-CD83, anti-CD86, and anti–human histocompatibil-
ity leukocyte antigen (HLA)–DR (BD Biosciences).
Nonreactive isotype-matched antibodies (Becton Dickin-
son) were used as controls. Post-electroporation eGFP
expression was assessed, compared with expression by
mock-electroporated DCs. Flow cytometry analyses used
a Cytomics FC500 flow cytometer (Beckman Coulter)
or LSRFortessa cell analyzer (BD Biosciences). Gateswere set for collection and analysis of at least 20,000
live events. Data were analyzed with FlowJo software
(TreeStar).
Allogeneic mixed leukocyte reactions (MLRs)
Mock-, eGFP mRNA-, and human WT1 mRNA-
electroporated moDCs or LCs were separately added in
serial doses (1:10 to 1:1000, moDC:T) to triplicate wells
of 1 × 105 allogeneic T cells in 96 round-bottomed well
plates (Corning Life Sciences). Final volume was 100 μL/
well of complete RPMI-10% heat-inactivated, NHS
serum. Responder allogeneic T cell proliferation was me-
asured by either: 1) incorporation of methyl-[3H]thy-
midine ([3H]TdR, 1 μCi/well; New England Nuclear,
Division of PerkinElmer Life Sciences) during the last 8
hours of a 5-day culture, as measured in a beta scintilla-
tion counter (Betaplate; Wallac, Division of PerkinElmer
Life Sciences), or 2) colorimetric assay according to
manufacturer's instructions (CellTiter96 Aqueous One
Solution Cell Proliferation Assay MTS; Promega).
Statistics
Student t test was used for each pairwise comparison.
One-way analysis of variance was used for multiple
group comparisons. A P value less than .05 was consi-
dered statistically significant.
Results
The transfection efficiency of mRNA electroporation
varies with the maturation status of moDCs and LCs
Immature and 24-hour, partially-matured moDCs and
LCs were electroporated with eGFP mRNA. After elec-
troporation, cells were immediately returned to culture
for at least 24 hours of maturation before being assessed
for eGFP expression as an index of transfection effi-
ciency. As shown in Figure 1A, transfection efficiency
was higher for immature than for partially-matured
moDCs (peak value at 24 hours: 77.9 ± 12.4% for im-
mature cells and 59.4 ± 15.4% for partially-matured
cells). In contrast, transfection efficiency was higher for
partially-matured than for immature LCs (Figure 1B;
peak value at 48 hours: 67 ± 6.9% for partially-matured
cells and 55.2 ± 2.9% for immature cells). Thus, both the
type and maturation status of DCs influence mRNA
transfection efficiency.
Optimal electroporation parameters for immature
moDCs and partially-matured LCs were determined by
varying set voltage, number of electroporation pulses,
and amount of mRNA to maximize transfection effi-
ciency while minimizing cell loss. For immature moDCs,
best results were achieved with 700 V, 1 pulse, and 40 μg
mRNA. For partially-matured LCs, best results were
achieved with 700 V, 2 pulses, and 30 μg mRNA. Results




















































Figure 1 The maturation status of moDCs and LCs affects mRNA-electroporation transfection efficiency. Immature (□) and partially-
matured (■) moDCs (A, C) and LCs (B, D) were electroporated with eGFP-encoding mRNA. The transfection efficiency for each experimental
group was assessed by flow cytometry at the indicated time points. Pooled data (mean ± SD, n = 6 independent experiments) are shown for
moDCs (A) and LCs (B). *P < .05 and **P < .01 for comparisons between immature and mature groups. Representative histograms of eGFP
mRNA-electroporated immature moDCs (C) and partially-matured LCs (D) from one of six independent experiments are shown.
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more mature phenotype after mRNA electroporation
Immature moDC and LCs electroporated with eGFP
mRNA were incubated with or without standard inflam-
matory cytokines. After 24 hours, DCs were assessed by
flow cytometry for the upregulation of the maturation
and activation markers, CD83, CD80, and CD86 [14,15].
Electroporation had a mild direct effect on moDC ma-
turation based on expression of the prototypical DC
maturation marker, CD83 (Figure 3A; 10.68 ± 3.37%
pre-electroporation and 26.13 ± 3.34% post-electro-
poration), whereas electroporation markedly increased
the maturation of CD83+HLA-DRbright LCs (Figure 3A;
29.62 ± 2.8% pre-electroporation and 96.92 ± 0.81%
post-electroporation). Electroporation induced greater
overall CD80 expression by LCs (Figure 3B; 33.36 ±
1.65% pre-electroporation and 77.03 ± 5.54% post-
electroporation) than moDCs (Figure 3B; 4.9 ± 2.1% pre-
electroporation and 35.88 ± 7.11% post-electroporation);fold increase of CD80 expression was greater for moDCs
(7.3-fold increase for moDC and 2.3-fold increase for
LCs). Electroporation had a similar effect on CD86 ex-
pression by moDCs (Figure 3C; 37.83 ± 3.12% pre-
electroporation and 73 ± 5.77% post-electroporation)
and LCs (Figure 3C; 27.44 ± 2.11% pre-electroporation
and 78.65 ± 3.12% post-electroporation). For either DC
subtype, electroporation did not impair terminal, inflam-
matory cytokine-induced maturation.
Cell loss and viability of moDCs and LCs after
electroporation and cryopreservation
Electroporation of cells can induce cell death due to the
deleterious effects of direct electrical current and disrup-
tion of the cell membrane. Electroporation of immature
and partially-matured moDCs and LCs resulted in up to
approximately 40% initial cell death, as determined by
trypan blue exclusion on direct hemacytometer counts
(Figure 4A).

























































Figure 2 Optimization of mRNA-electroporation conditions. Immature moDCs (A-C) and partially-matured LCs (D-F) were electroporated
with eGFP-encoding mRNA under different conditions of set voltage, number of electroporation pulses, or amount of mRNA. Only one of the
three parameters was varied in any given set of tested conditions, as summarized in each panel. Cells were assessed for viability (○) by trypan
blue exclusion and transfection efficiency (■) by flow cytometry.
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for 24 hours, and cell viability was reassessed. Immature
and mature moDCs and LCs demonstrated >85% viabi-
lity (Figure 4B; 94.2 ± 3.0% for immature moDCs and
88.7 ± 6.3% for immature LCs; 87.1 ± 7.1% for partially-
matured moDCs and 92.9 ± 3.8% for partially-matured
LCs).
The viability of both DC subtypes was further evalu-
ated after cryopreservation, with no significant difference
in survival between moDCs and LCs immediately after
thawing (Figure 4C; 79.2 ± 9.8% for immature moDCs
and 83.6 ± 5.4% for immature LCs; 82.3 ± 5.2% for
partially-matured moDCs and 84.4 ± 5.4% for partially-
matured LCs) or after thawing and resting for 24 hours
(Figure 4D; 96.8 ± 2.7% for immature moDCs and 94.8 ±
6.7% for immature LCs; 95.5 ± 8.4% for partially-matured
moDCs and 94.9 ± 4.2% for partially-matured LCs). These
anticipated yields are reproducible and inform the re-
quired number of starting cells.
MoDCs and LCs electroporated with mRNA retain
transgene expression after cryopreservation
Immature and mature moDCs and LCs were electro-
porated with eGFP mRNA, and post-electroporationeGFP expression was determined by flow cytometry.
Cells were then cryopreserved, and post-thaw eGFP
expression was compared with expression prior to
cryopreservation. Retention of protein expression was
similar between immature and mature moDCs and
LCs (Figure 5).
mRNA-electroporated moDCs and LCs remain potent
stimulators of allogeneic T cells in mixed leukocyte
reactions
Having shown that mRNA-electroporated moDCs and
LCs possess the ability to respond normally to inflam-
matory cytokines by upregulating phenotypic markers of
maturation and activation, we further assessed their
functional capacity to stimulate resting allogeneic T cell
proliferation. While distinct DC subtypes have different
capacities to stimulate CD8+ CTLs [14,15], their com-
parable stimulation of bulk allogeneic T cell proliferation
in MLRs remains a standard assay of overall DC im-
munogenicity [14]. MoDCs and LCs were therefore
electroporated with eGFP or WT1 mRNA, or were
mock electroporated with no mRNA and then matured
with inflammatory cytokines for 24 hours. The resulting
mature moDCs (Figure 6A, left panel) or LCs (Figure 6A,
Figure 3 mRNA electroporation induces the maturation and activation of LCs to a greater magnitude than for moDCs. Immature moDCs
and LCs were electroporated with eGFP mRNA and then cultured with (+) or without (−) standard maturation-inducing inflammatory cytokines.
After 24 hours, cells in each experimental group were compared with pre-electroporation controls by flow cytometry for the expression of
phenotypic markers of DC maturation and activation, based on the upregulation of (A) CD83, (B) CD80, and (C) CD86, respectively. Representative dot
plots of eGFP mRNA-electroporated moDCs and LCs from one of three independent experiments are shown in the top row. Pooled data for each
experimental group (mean ± SD, n = 3 independent experiments) are shown in the bottom row (gray bar = pre-electroporation control, white
bar = post-electroporation without inflammatory cytokines, black bar = post-electroporation with inflammatory cytokines). *P < .05, **P < .01,





























































Figure 4 Cell recovery and viability of moDCs and LCs after electroporation and cryopreservation. Immature (□) and partially-matured (■)
moDCs and LCs were electroporated with eGFP-encoding mRNA, without purification by HLA-DR selection a priori. (A) Immediate post-
electroporation viable cell recovery relative to the total number of cells electroporated was assessed by trypan blue exclusion (mean ± SD, n = 4
independent experiments). (B) Surviving cells from (A) were returned to culture, and cell viability was assessed 24 hours after electroporation,
relative to initial number of cells returned to culture after electroporation (mean ± SD, n = 4 independent experiments). (C) After at least 24
hours in culture, cells from (B) were cryopreserved. Upon subsequent thawing, immediate post-thaw viability was assessed relative to initial
number of cells frozen (mean ± SD, n = 4 independent experiments). (D) After 24 hours in culture, thawed cells from (C) were reassessed for
viability (mean ± SD, n = 4 independent experiments).


























Figure 5 mRNA-electroporated moDCs and LCs retain eGFP
expression after cryopreservation. Immature (□) and partially-
matured (■) moDCs and LCs were electroporated with eGFP mRNA
and cryopreserved. After thawing, eGFP expression for each
experimental group was measured by flow cytometry and compared
with pre-cryopreservation eGFP expression values to determine
percent retention of eGFP expression. Pooled data are shown for each
experimental group (mean ± SD, n = 3 independent experiments,
ns = not significant).
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fixed number of purified allogeneic T cells and incubated
for 5 days. Allogeneic T cell proliferative responses were
measured by [3H]TdR uptake over the last 8 hours of a




















































Figure 6 mRNA-electroporated moDCs and LCs remain potent induce
cryopreservation and thawing. (A) MoDCs and LCs, as indicated on the
mock-electroporated with no mRNA (□). After electroporation, DCs were te
cells for five days in allogeneic MLRs. DC:T ratios ranged from 1:10 to 1:100
hours of culture was measured as an index of DC immunogenicity (triplica
preservation of allo-stimulatory capacity in MLRs after cryopreservation and
compared with non-cryopreserved mature moDCs (■). Culture conditions w
measured by a colorimetric assay (triplicate means ± SEM, n = 3 independ
T cells alone.of proliferation when cultured with moDC and LCs
electroporated under the three experimental conditions
(Figure 6A). DCs also retained their allo-stimulatory
capacity after cryopreservation and thawing, as mea-
sured by a colorimetric proliferation assay (Figure 6B).
Thus, both moDCs and LCs remain functionally potent
stimulators of allogeneic T cell proliferation, unaffected
by prior mRNA electroporation or cryopreservation and
despite their differences in CTL stimulation.
Discussion
This study establishes different conditions for the suc-
cessful electroporation and expression of full-length
mRNA in human CD34+ HPC-derived LCs versus blood
moDCs, for use in clinical DC-based vaccine trials. Elec-
troporation efficiency depends on the maturation status
of the two DC subtypes, with partially-matured LCs
showing more efficient transfection than immature LCs
and immature moDCs showing more efficient trans-
fection than mature moDCs. Electroporation favorably
induces the maturation of CD83+HLA-DRbright LCs,
whereas electroporation has no direct effect on moDC
maturation. LCs and moDCs are equally sensitive to the
direct effects of electroporation with decreased viability
immediately after electroporation. LCs and moDCs also
demonstrate similar retention of transgene expression
after cryopreservation. Importantly, both DC subtypes




























rs of allogeneic T cell proliferation, including after
x axes, were electroporated with WT1 mRNA (○), eGFP mRNA (△), or
rminally matured for 24 hours and then cultured with allogeneic T
0. [3H]TdR uptake by proliferating allogeneic T cells over the final 8
te means ± SEM, n = 3 independent experiments). (B) To assess
thawing, WT1 mRNA-electroporated moDCs (△) and LCs (○) were
ere otherwise exactly the same as in (A). T cell proliferation was
ent experiments). Dotted line represents
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despite their inherent differences in capacity for CD8+
CTL stimulation [14-17].
For moDCs, our observation of greater transfection ef-
ficiency of immature cells than for mature cells differs
from another study in which the transfection efficiency
of immature and mature moDCs was roughly equivalent
[18]. Various electroporation conditions with disparate
degrees of transfection efficiency, however, have been
reported for moDCs [8,19-21]. These discrepancies un-
derscore the importance of revalidating electroporation
parameters for any differences in electroporation ma-
chine, voltage, number of pulses, cell concentration, or
amount of mRNA, as depicted in Figure 2.
Peak transfection efficiency is lower for LCs than for
moDCs. Likely contributing to this difference is that
moDCs are derived from a more differentiated and com-
mitted starting population than are LCs, resulting in
greater cell population purity. Thus the difference in ab-
solute transfection values would have favored moDCs, as
the LCs would have had other contaminating, non-LCs
competing for mRNA uptake during electroporation.
Purification of LCs by HLA-DR selection on magnetic
beads is one potential solution to increase transfection
efficiency, but this should not be necessary to the extent
that one can quantify the proportion of electroporated
LCs by flow cytometry in the final antigen-presenting
cell population.
Consistent with previous studies [22-24], the immedi-
ate post-electroporation viability of mRNA-electropo-
rated DCs is less than the initial starting population.
Subsequent survival of viable cells is minimally affected,
however. Cryopreservation can further decrease cell re-
covery, so an appropriate excess of electroporated DCs
should be aliquoted for cryopreservation. This will en-
sure sufficient DC yields, irrespective of moDC or LC
subtype, from thawed aliquots for vaccination.
We previously reported the results of a clinical trial in
AJCC stage III/IV melanoma patients, comparing vac-
cination with peptide-loaded LCs versus peptide-loaded
moDCs [12]. The rationale for this trial was based on
our established findings in vitro that human LCs are
consistently superior to moDCs on a cell-for-cell basis
in eliciting MHC-restricted, antigen-specific CTLs
[14,16], which has been corroborated by other investi-
gators [15,17]. A clinical trial conducted by Banchereau
and colleagues for similarly advanced-stage melanoma
patients using bulk CD34+ HPC-derived DCs, which in-
cluded LCs, pulsed with a mixture of melanoma-derived
peptides, resulted in durable immune responses asso-
ciated with long-term survival [25]. Although patients
treated on the LC arm of our trial generated significantly
greater reactivity against tyrosinase than those treated
with moDCs, significant differences were not observedfor gp100 or the control fluMP antigen [12]. This begged
the obvious question as to whether loading class I
MHC-restricted single peptides onto any defined DC
subtype would ever be sufficient to stimulate durable
immunity against tumor antigens.
Our group has since discovered that LCs from healthy
volunteers, electroporated with Wilms’ tumor 1 (WT1)
mRNA, promote sustained presentation of antigenic
peptides, which in conjunction with IL15R-α/IL15, in-
duce robust autologous, WT1-specific CTLs [16]. The
CTLs develop after just 7 days’ stimulation without
exogenous cytokine supplementation and lyse MHC-
restricted targets, including primary WT1-expressing
blasts from leukemia patients. MoDCs, in contrast, re-
quire exogenous IL15 to promote immune responses
comparable to LCs. Thus LCs provide a more favorable
cytokine milieu for the activation of T cells than do
moDCs, thereby explaining their superior induction of
antigen-specific CTLs in the absence of exogenous cyto-
kines. These data support the use of mRNA-electro-
porated LCs, or IL15-supplemented moDCs, as cancer
vaccines to overcome tolerance against self-differentia-
tion tumor antigens. The pivotal role of IL15 in LC-
mediated stimulation of CTLs has also been confirmed
using individual peptides rather than mRNA encoding
full-length protein [17,25].
Given the importance of LCs and their provision of
IL15, as well as the possible application of IL15-
supplemented moDCs in DC-based vaccines, we thought
it essential to ascertain the optimal conditions for their
respective electroporation with mRNA to express full-
length protein. Such expression enables cells to process
and present antigenic peptides tailored to their own
MHCs, allowing clinical investigators to move beyond
single defined peptides for a given tumor, if they are
even known, and circumvent the limitations of specific
HLA types in patients. There may be additional, as yet
undiscovered reasons for LCs’ potency over moDCs,
which may nonetheless prove sufficiently compelling to
favor LCs in vaccine trials. MoDCs offer the potential
benefit of activating NK cells via IL12p70 [26]. LCs do
not secrete IL12p70 but maintain NK cell viability via
IL15 [14,26]. It will be important to determine whether
moDCs supplemented with IL15 are an adequate substi-
tute for LCs, or whether the two DC subtypes should be
used in combination to capitalize on the efficacy of
moDCs in activating NK cells and the potency of LCs in
inducing CD8+ CTLs.
Conclusions
Enhanced antigen presentation by DCs can be achieved
with mRNA electroporation but requires modifying con-
ditions to the specific DC subtype. Our findings with
LCs and moDCs provide key parameters on the optimal
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ation, and anticipated cell losses and yields. Investigators
should now have the tools in hand to address key ques-
tions about DC-based cancer immunotherapy in vivo in
humans, with reasonable maintenance of LC or moDC
viability and preservation of the activated phenotype and
baseline immunostimulatory capacity.Abbreviations
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